Literature DB >> 31222183

Translatable gene therapy for lung cancer using Crispr CAS9-an exploratory review.

Jishnu Nair1, Abhishek Nair1, Soundaram Veerappan1, Dwaipayan Sen2.   

Abstract

Gene therapy using CRISPR Cas9 technique is rapidly gaining popularity among the scientific community primarily because of its versatility, cost-effectiveness, and high efficacy. While the laboratory-based experiments and findings making use of CRISPR as a gene editing tool are available in ample amounts, the question arises that how much of these findings are actually translatable into measures helping in combating particular disease conditions. In this review, we highlight the important studies and findings done till now in the perspective of lung cancer with an in-depth analysis of various clinical trials associated with the use of CRISPR Cas9 technology in the field of cancer research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31222183     DOI: 10.1038/s41417-019-0116-8

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  81 in total

1.  The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification.

Authors:  William D Travis; Elisabeth Brambilla; Andrew G Nicholson; Yasushi Yatabe; John H M Austin; Mary Beth Beasley; Lucian R Chirieac; Sanja Dacic; Edwina Duhig; Douglas B Flieder; Kim Geisinger; Fred R Hirsch; Yuichi Ishikawa; Keith M Kerr; Masayuki Noguchi; Giuseppe Pelosi; Charles A Powell; Ming Sound Tsao; Ignacio Wistuba
Journal:  J Thorac Oncol       Date:  2015-09       Impact factor: 15.609

Review 2.  FHIT: from gene discovery to cancer treatment and prevention.

Authors:  Yuri Pekarsky; Nicola Zanesi; Alexey Palamarchuk; Kay Huebner; Carlo M Croce
Journal:  Lancet Oncol       Date:  2002-12       Impact factor: 41.316

3.  Inactivation of human SRBC, located within the 11p15.5-p15.4 tumor suppressor region, in breast and lung cancers.

Authors:  X L Xu; L C Wu; F Du; A Davis; M Peyton; Y Tomizawa; A Maitra; G Tomlinson; A F Gazdar; B E Weissman; A M Bowcock; R Baer; J D Minna
Journal:  Cancer Res       Date:  2001-11-01       Impact factor: 12.701

4.  International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising.

Authors:  Susan S Devesa; Freddie Bray; A Paloma Vizcaino; D Max Parkin
Journal:  Int J Cancer       Date:  2005-11-01       Impact factor: 7.396

5.  Projections of number of cancer cases in India (2010-2020) by cancer groups.

Authors:  Ramnath Takiar; Deenu Nadayil; A Nandakumar
Journal:  Asian Pac J Cancer Prev       Date:  2010

6.  Caveolin-1 inhibits breast cancer growth and metastasis.

Authors:  Erica K Sloan; Kym L Stanley; Robin L Anderson
Journal:  Oncogene       Date:  2004-10-14       Impact factor: 9.867

7.  Epidemiology of lung cancer in India: focus on the differences between non-smokers and smokers: a single-centre experience.

Authors:  V Noronha; R Dikshit; N Raut; A Joshi; C S Pramesh; K George; J P Agarwal; A Munshi; K Prabhash
Journal:  Indian J Cancer       Date:  2012 Jan-Mar       Impact factor: 1.224

8.  Clinico-pathological profile of lung cancer at AIIMS: a changing paradigm in India.

Authors:  Prabhat Singh Malik; Mehar Chand Sharma; Bidhu Kalyan Mohanti; N K Shukla; Svs Deo; Anant Mohan; Guresh Kumar; Vinod Raina
Journal:  Asian Pac J Cancer Prev       Date:  2013

9.  Clinico-pathology of lung cancer in a regional cancer center in Northeastern India.

Authors:  Sanjeet Kumar Mandal; Thaudem Tomcha Singh; Takhenchangbam Dhaneshor Sharma; Venkatesan Amrithalingam
Journal:  Asian Pac J Cancer Prev       Date:  2013

10.  Evidence of cumulative gene losses with progression of premalignant epithelial lesions to carcinoma of the bronchus.

Authors:  L Thiberville; P Payne; J Vielkinds; J LeRiche; D Horsman; G Nouvet; B Palcic; S Lam
Journal:  Cancer Res       Date:  1995-11-15       Impact factor: 12.701

View more
  6 in total

1.  Applications of CRISPR/Cas technology against drug-resistant lung cancers: an update.

Authors:  Mayank Chaudhary; Pooja Sharma; Tapan Kumar Mukherjee
Journal:  Mol Biol Rep       Date:  2022-09-12       Impact factor: 2.742

Review 2.  Applications and challenges of CRISPR-Cas gene-editing to disease treatment in clinics.

Authors:  Wenyi Liu; Luoxi Li; Jianxin Jiang; Min Wu; Ping Lin
Journal:  Precis Clin Med       Date:  2021-07-10

Review 3.  Genome-editing approaches and applications: a brief review on CRISPR technology and its role in cancer.

Authors:  Narmadhaa Siva; Sonal Gupta; Ayam Gupta; Jayendra Nath Shukla; Babita Malik; Nidhi Shukla
Journal:  3 Biotech       Date:  2021-02-26       Impact factor: 2.406

4.  Inadvertent nucleotide sequence alterations during mutagenesis: highlighting the vulnerabilities in mouse transgenic technology.

Authors:  Anuran Ghosh; Rituparna Chakrabarti; Praphulla Chandra Shukla
Journal:  J Genet Eng Biotechnol       Date:  2021-02-11

Review 5.  CRISPR-Cas deployment in non-small cell lung cancer for target screening, validations, and discoveries.

Authors:  K Sreedurgalakshmi; R Srikar; Reena Rajkumari
Journal:  Cancer Gene Ther       Date:  2020-11-15       Impact factor: 5.987

Review 6.  Novel Insights into the Therapeutic Potential of Lung-Targeted Gene Transfer in the Most Common Respiratory Diseases.

Authors:  Malik Bisserier; Xiao-Qing Sun; Shahood Fazal; Irene C Turnbull; Sébastien Bonnet; Lahouaria Hadri
Journal:  Cells       Date:  2022-03-12       Impact factor: 7.666

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.